Co-Diagnostics, Inc. (CODX)

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast

Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies

Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform

Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer

Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand

Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test

Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States

Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement

Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities

Is Co-Diagnostics National Security's Next Diagnostic Pick?

Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara